Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results for the quarter ended on 31st December, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Denis Chem Lab Ltd, which manufactures parenteral (transfusion) products, submitted its unaudited financial results for the quarter ended 31st December 2025. Revenue from operations rose to Rs. 4,551.83 lakh, up about 6.3% from Rs. 4,284.13 lakh in the same quarter last year. Profit after tax jumped sharply to Rs. 332.16 lakh versus Rs. 176.14 lakh in Q3 FY25, an increase of roughly 89%, driven by lower raw material and other expenses relative to revenue. For the nine-month period (Apr-Dec 2025), revenue grew modestly to Rs. 13,496.55 lakh and PAT rose to Rs. 800.92 lakh from Rs. 736.83 lakh. The auditor (Shah & Shah Associates) issued an unmodified (clean) limited review report, with no qualifications or emphasis of matter.
Strong YoY profit growth, despite modest revenue increase, signals healthy margin expansion and cost control - positive for shareholders. The clean auditor opinion and zero reported debt/income from operations add to the comfort, though the sequential dip in revenue from Q2 FY26 may warrant a closer look.